Gastroesophageal (GE) junction and gastric adenocarcinomas can be treated with immune checkpoint inhibitors (ICI), which specifically target the cytotoxic T lymphocyte antigen 4 (CTLA-4) and program cell death protein 1 (PD-1) and its receptor. Here, PDCD1 is linked to gastric adenocarcinoma.